Live from the NIH registry
Studies recruiting near Anchorage right now
Top 25 of 115 recruiting studies, sorted by proximity — each links to its official registry page
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
Arrhythmia, Bradycardia
N/A
Observational 20,000 participants sought
Research site — Anchorage, Alaska (26.8 mi)
· Sponsor: Medtronic
Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer
Phase 3
Interventional 600 participants sought
Research Site — Anchorage, Alaska (26.8 mi)
· Sponsor: AstraZeneca
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
Phase 3
Interventional 1,875 participants sought
Providence Alaska Medical Center — Anchorage, Alaska (26.8 mi)
· Sponsor: National Cancer Institute (NCI)
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Non-Small Cell Lung Cancer
Phase 3
Interventional 675 participants sought
Research Site — Anchorage, Alaska (26.8 mi)
· Sponsor: AstraZeneca
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma
Phase 2
Interventional 130 participants sought
Alaska Oncology & Hematology, LLC — Anchorage, Alaska (26.8 mi)
· Sponsor: Hoffmann-La Roche
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
Refractory Differentiated Thyroid Gland Carcinoma
Phase 3
Interventional 264 participants sought
Anchorage Associates in Radiation Medicine — Anchorage, Alaska (26.8 mi)
· Sponsor: ECOG-ACRIN Cancer Research Group
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic
Phase 3
Interventional 680 participants sought
Alaska Oncology and Hematology — Anchorage, Alaska (26.8 mi)
· Sponsor: Pfizer
A Double-blind, Randomized Controlled Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of Pegloticase Administration Via Subcutaneous and Intravenous Routes Both With Methotrexate in Participants With Uncontrolled Gout
Uncontrolled Gout
Phase 3
Interventional 270 participants sought
Orthopedic Physicians Alaska — Anchorage, Alaska (26.8 mi)
· Sponsor: Amgen
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
Solid Tumors
Phase 3
Interventional 588 participants sought
Investigative Site US016 — Anchorage, Alaska (26.8 mi)
· Sponsor: Incyte Corporation
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Previously Treated Non-Small Cell Lung Cancer
Phase 2, Phase 3
Interventional 10,000 participants sought
Anchorage Associates in Radiation Medicine — Anchorage, Alaska (26.8 mi)
· Sponsor: SWOG Cancer Research Network
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma
Phase 3
Interventional 382 participants sought
Anchorage Associates in Radiation Medicine — Anchorage, Alaska (26.8 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Ovarian Cancer, Fallopian Tube Cancer
Phase 3
Interventional 770 participants sought
Alaska Women's Cancer Care ( Site 0096) — Anchorage, Alaska (26.8 mi)
· Sponsor: Merck Sharp & Dohme LLC
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Multiple conditions
Phase 2
Interventional 314 participants sought
Anchorage Associates in Radiation Medicine — Anchorage, Alaska (26.8 mi)
· Sponsor: National Cancer Institute (NCI)
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
Anaplastic Kidney Wilms Tumor, Recurrent Kidney Wilms Tumor
Phase 2
Interventional 256 participants sought
Providence Alaska Medical Center — Anchorage, Alaska (26.8 mi)
· Sponsor: Children's Oncology Group
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma
Phase 3
Interventional 360 participants sought
Alaska Women's Cancer Care — Anchorage, Alaska (26.8 mi)
· Sponsor: National Cancer Institute (NCI)
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
Malignant Female Reproductive System Neoplasm, Malignant Solid Neoplasm
Phase 2
Interventional 70 participants sought
Alaska Women's Cancer Care — Anchorage, Alaska (26.8 mi)
· Sponsor: National Cancer Institute (NCI)
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Breast Neoplasms, Neoplasm Metastasis
Phase 3
Interventional 800 participants sought
Alaska Oncology and Hematology — Anchorage, Alaska (26.8 mi)
· Sponsor: Eli Lilly and Company
Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC
NSCLC, Non-small Cell Lung Cancer
Phase 3
Interventional 430 participants sought
Alaska Oncology and Hematology — Anchorage, Alaska (26.8 mi)
· Sponsor: Revolution Medicines, Inc.
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Breast Cancer
N/A
Observational 30,000 participants sought
Providence Alaska Medical Center — Anchorage, Alaska (26.8 mi)
· Sponsor: Agendia
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Intracranial Meningioma, Recurrent Meningioma
Phase 2
Interventional 124 participants sought
Anchorage Associates in Radiation Medicine — Anchorage, Alaska (26.8 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma
Phase 2
Interventional 80 participants sought
Providence Alaska Medical Center — Anchorage, Alaska (26.8 mi)
· Sponsor: Children's Oncology Group
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
Endometrial Adenocarcinoma
Phase 2
Interventional 350 participants sought
Alaska Women's Cancer Center — Anchorage, Alaska (26.8 mi)
· Sponsor: Acrivon Therapeutics
Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
Prostate Adenocarcinoma, Stage IIIB Prostate Cancer AJCC v8
Phase 2
Interventional 44 participants sought
Anchorage Associates in Radiation Medicine — Anchorage, Alaska (26.8 mi)
· Sponsor: SWOG Cancer Research Network
MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
Lumbar Spinal Stenosis
N/A
Observational 8,000 participants sought
AA Spine & Pain Clinic — Anchorage, Alaska (26.8 mi)
· Sponsor: Stryker Instruments
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
Central Nervous System Nongerminomatous Germ Cell Tumor, Choriocarcinoma
Phase 2
Interventional 160 participants sought
Providence Alaska Medical Center — Anchorage, Alaska (26.8 mi)
· Sponsor: Children's Oncology Group